Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Tango Therapeutics Inc. — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.10B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is more actively traded (3,438,781 versus 1,688,674). Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 17 Days and Tango Therapeutics Inc. for 0 Days on average.
| FLRN | TNGX | |
|---|---|---|
Market Cap | $3.10B | $3.74B |
Volume | 1,688,674 | 3,438,781 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $32.90 |
52-Week Low | $30.65 | $7.50 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.77 with no recent price change. Technical indicators signal a bearish trend, while recent news highlights its appeal as a floating-rate bond ETF amid rising interest rates. The ETF has announced several small dividends for 2026, but key financial ratios like P/E and P/B are unavailable.
The outlook for FLRN is mixed; its near-zero duration and floating-rate structure offer protection against rate hikes, attracting institutional interest. However, significant financial sector exposure and bearish technical signals pose risks. Investors should weigh the defensive characteristics against market volatility and sector-specific headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
